Clinical trials: NSCLC (non-small Cell Lung Cancer)
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population.
- Trial name
- NCT02974426
- Testing
- PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Chest Hospital
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00857025
- Testing
- beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer
Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
A prospective, single-arm, phase II trial of Adebrelimab combined with bevacizumab and albumin paclitaxel in advanced non-squamous non-small cell lung cancer after first-line immunotherapy progression.
- Trial name
- NCT05738317
- Testing
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Xiaorong Dong
Carcinoma, Non-Small-Cell Lung
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable…
- Trial name
- PACIFIC-5 (NCT03706690)
- Testing
- Durvalumab
- Where
- 87 sites in China, Hong Kong and 8 more
- Volunteers
- 407 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
- Trial name
- NCT00986284
- Testing
- gefitinib
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
This is an open label, prospective, single center Phase II clinical study. Intended to evaluate the main pathological response rate (MPR) and safety of stereotactic immunosensitized radiotherapy combined with Evoximab…
- Trial name
- NCT06391008
- Testing
- Stereotactic radiotherapy, Evoximab, Pemetrexed
- Volunteers
- 44 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-small Cell Lung Cancer
Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment
The object of this study is to identify the combined effect of ANKL and doublet chemotherapy in advanced NSCLC. The investigators design the combination of ANKL and approved chemotherapy as the 3rd and 4th courses in the patients…
- Trial name
- ANKL-2 (NCT02370017)
- Testing
- ANKL(Ex vivo-expanded NK cell enriched lymphocytes)
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- The Catholic University of Korea
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.
- Trial name
- NCT07034391
- Testing
- denosumab combined anti-PD-1 inhibitor with chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- China Medical University, China
Metastatic Non-small Cell Lung Cancer, Neoplasm
Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
This retrospective, single-center observational cohort study evaluates inflammatory-metabolic, cachexia-related, and computed tomography (CT)-derived body-composition markers in patients with metastatic non-small cell lung cancer…
- Trial name
- SARC-CTI (NCT07192926)
- Testing
- Immune Checkpoint Inhibitor-Based Therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 155 people
- Sponsor
- Ankara Etlik City Hospital
Non Small Cell Lung Cancer (NSCLC)
Nitroglycerin in Non-small Cell Lung Cancer
Nitroglycerin is a nitric oxide donor which is mainly known as a vasodilating agent used in ischemic heart disease. It has also been shown to increase tumor blood flow in animal and human tumors.
- Trial name
- Nitroglycerin (NCT01210378)
- Testing
- Nitroglycerin patch
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- Maastricht Radiation Oncology
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00021060
- Testing
- paclitaxel, carboplatin, bevacizumab
- Where
- United States
- Volunteers
- 842 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00843726
- Testing
- Arm 1 stereotactic body radiation therapy, Arm II stereotactic body radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence.
- Trial name
- NCT06406608
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Value of Physical Capacity Tests in Lung Cancer
The study examines the physical capacity of lung cancer patients assessed with the six minute walk test and handgrip strength. Demographic and selfreported exercise behavior is registered to explore correlations to functional and…
- Trial name
- NCT01943578
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma
CAIX-targeted PET/CT in Solid Tumors
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance.
- Conditions
- Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer
- Trial name
- CAIX-PET (NCT07833085)
- Testing
- 68Ga-CAIX
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Non-squamous Non-small Cell Lung Cancer
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer…
- Trial name
- BEVERLY (NCT02633189)
- Testing
- Erlotinib, Bevacizumab
- Where
- 55 sites in Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Carcinoma, Non-Small-Cell Lung
Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
The study will take place over a period of 27 months. The recruitment phase will last approximately 24 months and each patient will participate for approximately 3 months.
- Trial name
- NCT02483416
- Where
- 36 sites in France
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Immune-related Colitis
EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
The photoactivating agent UVADEX (methoxsalen) is used in conjunction with extracorporeal photopheresis (ECP) as an immunomodulatory therapy approved for the treatment of cutaneous T-cell lymphoma.
- Trial name
- EPIC (NCT06646016)
- Testing
- Methoxsalen, Infliximab, Vedolizumab
- Where
- United States
- Sponsor
- Therakos LLC
Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Surgical intervention remains the primary treatment option for early-stage lung cancer. With the proven efficacy of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), neoadjuvant immunotherapy has…
- Trial name
- NCT06837948
- Testing
- PM8002, Sintilimab, Nab-paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.